Articles by Patricia K. Coyle, MD
An overview of the clinical subtypes of multiple sclerosis and factors that help neurologists distinguish between each type for an appropriate diagnosis.
Clyde E. Markowitz, MD, comments on the growing role of magnetic resonance imaging to help diagnose multiple sclerosis and highlights characteristics of lesions he looks at during a diagnostic evaluation.
Patricia K. Coyle, MD, highlights revisions to the McDonald diagnostic criteria for multiple sclerosis and emphasizes why health care professionals need to start referring to the criteria in a more standard fashion.
The Future of Managing Multiple Sclerosis
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
Fumarates for Treatment of RMS
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
S1P Receptor Modulators for Treatment of RMS
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
Cladribine for Treatment of RMS
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
Anti-CD20 Monoclonal Antibodies for Treatment of RMS
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
Strategies for Choosing Initial Therapy in MS
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
OPTIMUM Phase 3 Trial: Secondary End Point Effect on Fatigue
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
TRIUMPHANT-MS Trial: Fatigue in MS
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
Multiple Sclerosis Fatigue
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
QoL Issues in the Management of Multiple Sclerosis
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
Challenges in Optimally Treating Multiple Sclerosis
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
Cerebrospinal Fluid in Diagnosing Multiple Sclerosis
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
Misdiagnosis of Multiple Sclerosis
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
Use of MRI in Diagnosing Multiple Sclerosis
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis
ByFred Lublin, MD,Patricia K. Coyle, MD,Scott Newsome, DO, MSCS, FAAN,Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC 
The director of the MS Comprehensive Care Center and interim chair of the department of neurology at Stony Brook University spoke to the importance of properly communicating with patients with MS as a physician.
The director of the MS Comprehensive Care Center and interim chair of the department of neurology at Stony Brook University spoke to the debates around halting and beginning treatment in patients with MS.
The director of the MS Comprehensive Care Center and interim chair of the department of neurology at Stony Brook University discussed the need for more originality in the MS pipeline.
The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute spoke about the importance of early treatment and identification of the condition.
While there isn’t one agent Coyle believes is held above the rest, she noted that the oral therapies have become popular due to ease of administration.
